Antiangiogènes dans les sarcomes des tissus mous
作者： Duffaud F , Salas S , Huynh T , Deville Jl
关键词: Cancer research 、 Soft tissue sarcoma 、 GiST 、 Cancer 、 Angiogenesis 、 Medicine 、 Neovascularization 、 Surgery 、 Monoclonal antibody 、 Soft tissue 、 Drug
摘要: Angiogenesis is an essential prerequisite in the growth and dissemination of soft tissue sarcoma. The understanding VEGF VEGFR pathway implication development non GIST sarcoma discovery antitumoral activity drugs that inhibit this other solid tumors, led to antiangiogenic anti sarcoma, as monoclonal antibody (bevacuzimab) or small molecules (tyrosine-kinase inhibitors VEGFR). This manuscript presents results first clinical trials have evaluated efficacy safety some angiogenesis sarcomas.
sci-hub.se 参考文章(25)
A. Nichol, C. Bajdik, R. Yerushalmi, C. Speers, M. L'Esperance, S. Tyldesley, K. A. Gelmon, I. Olivotto, Calculation of outcome estimates for synchronous bilateral breast cancer patients using Adjuvant Journal of Clinical Oncology. ,vol. 26, pp. 561- 561 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.561
Cornelius Kuhnen, Marcus Lehnhardt, Edina Tolnay, Thomas Muehlberger, Peter M. Vogt, Klaus-Michael Müller, Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours. Journal of Cancer Research and Clinical Oncology. ,vol. 126, pp. 219- 225 ,(2000) , 10.1007/S004320050036
A. J. Hayes, A. Mostyn-Jones, M. U. Koban, R. A'Hern, P. Burton, J. M. Thomas, Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma British Journal of Surgery. ,vol. 91, pp. 242- 247 ,(2004) , 10.1002/BJS.4398
D. Yi-Shin Kuo, Patrick Timmins, Stephanie V. Blank, Abbie L. Fields, Gary L. Goldberg, Anthony Murgo, Paul Christos, Scott Wadler, Carolyn D. Runowicz, Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. Gynecologic Oncology. ,vol. 100, pp. 160- 165 ,(2006) , 10.1016/J.YGYNO.2005.08.033
Andrew L. Feldman, Ho Pak, James C. Yang, H. Richard Alexander, Steven K. Libutti, Serum endostatin levels are elevated in patients with soft tissue sarcoma Cancer. ,vol. 91, pp. 1525- 1529 ,(2001) , 10.1002/1097-0142(20010415)91:8<1525::AID-CNCR1161>3.0.CO;2-P
Vinod Raina, Manju Sengar, Nootan K. Shukla, Sankaranavamsam S. Deo, Bidhu K. Mohanty, Dayanand Sharma, Ruma Ray, Prasenjit Das, Goura K. Rath, Complete response from thalidomide in angiosarcoma after treatment of breast cancer. Journal of Clinical Oncology. ,vol. 25, pp. 900- 901 ,(2007) , 10.1200/JCO.2006.09.7261
Ullrich Graeven, Niko Andre, Eike Achilles, Carsten Zornig, Wolff Schmiegel, Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. Journal of Cancer Research and Clinical Oncology. ,vol. 125, pp. 577- 581 ,(1999) , 10.1007/S004320050319
Stefan Sleijfer, Winette T.A. van der Graaf, Jean‐Yves Blay, Angiogenesis inhibition in non-GIST soft tissue sarcomas. Oncologist. ,vol. 13, pp. 1193- 1200 ,(2008) , 10.1634/THEONCOLOGIST.2008-0188
Martine Van Glabbeke, Jaap Verweij, Ian Judson, Ole Steen Nielsen, EORTC Soft Tissue and Bone Sarcoma Group, Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas European Journal of Cancer. ,vol. 38, pp. 543- 549 ,(2002) , 10.1016/S0959-8049(01)00398-7
Steven DuBois, George Demetri, Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. ,vol. 109, pp. 813- 819 ,(2007) , 10.1002/CNCR.22455